GLP-1 and the FDA: How Drug Approval Works

The path from laboratory discovery to your weekly injection involves years of testing, billions of dollars, and rigorous FDA oversight. Understanding this process explains why brand-name semaglutide costs $1,350/month, why compounded versions are legal and affordable, and when we can expect retatrutide approval.

The FDA Approval Pipeline

503A Compounding: Why It Is Legal

FDA-registered 503A outsourcing facilities can legally compound copies of drugs on the FDA Drug Shortage List. Both semaglutide and tirzepatide have been on the shortage list, enabling compounding. These facilities must follow current Good Manufacturing Practices (cGMP), undergo FDA inspections, provide adverse event reporting, and produce with USP-grade ingredients. This legal pathway is how Trimi offers compounded semaglutide at $99/month and tirzepatide at $125/month.

Why Brand-Name GLP-1s Cost So Much

• R&D costs: $1-3 billion over 10-15 years to discover, develop, and test
• Manufacturing: Complex biologics production facilities cost hundreds of millions
• Marketing: DTC advertising and sales force costs in the hundreds of millions
• Patent period: Companies have limited exclusivity to recoup investment
• Demand pricing: High demand with limited competition enables premium pricing

Retatrutide FDA Timeline

Retatrutide is currently in Phase 3 (TRIUMPH program). Expected NDA submission: late 2026 or 2027. With priority review, approval could come 6 months after submission. Best case: late 2027. Likely case: 2028. Until then, compounded retatrutide is available through providers like Trimi.